ArticleJournal of thoracic disease2025
Compared with assessment via endoscopic examination, assessment through the examination of resected regional lymph nodes can significantly reduce the mortality rate of lung cancer patients: a retrospective study of 222,563 participants from the SEER database.
Article in Journal of thoracic disease, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Lymph node assessment is essential for determining treatment and evaluating the surgical scope in patients with lung cancer, thus significantly impacting survival prognosis. Surgical resection and endoscopic biopsy are the primary methods for obtaining lymph node samples, yet it remains controversial to determine which approach can provide greater benefit. This study aims to analyze the prognosis and survival outcomes of lung cancer patients who undergo assessment through the examination of resected regional lymph nodes, assessment via endoscopic examination, or assessment based on imaging modalities. Methods: Data from the Surveillance, Epidemiology, and End Results (SEER) database, comprising 222,563 participants, were analyzed. The outcome variables were overall survival (OS) and lung cancer-specific mortality, while the primary variable was the method of lymph node assessment. Life table, Kaplan-Meier survival, and Cox proportional hazards analyses were conducted, with log-rank Mantel-Cox, Breslow generalized Wilcoxon, and Tarone-Ware tests being applied for intergroup comparisons. Results: Compared to endoscopic biopsy, lymph node resection examination reduced the risk of death by 15.7% (P<0.001) and the lung cancer-specific mortality rate by 15.5% (P<0.001). Lung cancer patients who underwent regional lymph node resection examination had higher OS rates at 1, 2, 3, 5, 10, and 15 years by 44%, 49%, 47%, 42%, 28%, and 20%, respectively, compared to those who underwent endoscopic biopsy. Additionally, their cancer-specific survival rates were higher at the corresponding time points by 13%, 16%, 17%, 17%, 18%, and 13%, respectively. The mean OS period for patients who underwent endoscopic lymph node biopsy was 25.071 months, whereas for lung cancer patients who underwent regional lymph node resection examination, the average OS was 87.403 months. Conclusions: In patients with lung cancer, lymph node resection examination significantly reduces mortality and improves survival as compared to endoscopic biopsy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.